Aurinia Pharmaceuticals (NASDAQ:AUPH) Issues Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) released its earnings results on Thursday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01, Briefing.com reports. Aurinia Pharmaceuticals had a negative return on equity of 11.75% and a negative net margin of 24.31%. The firm had revenue of $57.10 million for the quarter, compared to analyst estimates of $54.25 million. During the same quarter last year, the firm posted ($0.08) EPS. The company’s revenue was up 37.6% on a year-over-year basis.

Aurinia Pharmaceuticals Trading Down 2.0 %

Aurinia Pharmaceuticals stock opened at $5.50 on Friday. Aurinia Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $11.15. The stock has a market cap of $786.61 million, a price-to-earnings ratio of -12.79 and a beta of 1.44. The business has a 50 day moving average price of $5.52 and a two-hundred day moving average price of $5.76. The company has a quick ratio of 5.05, a current ratio of 5.60 and a debt-to-equity ratio of 0.19.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.